Another approval for clinical trials for centronuclear myopathies

Today, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved clinical trials of the drug DYN101. This drug regulates the production of the enzyme dynamin 2 in the body. This could lead to an improvement in the symptoms of people with various centronuclear myopathies (CNM) (those with mutations in the genes MTM1 and DNM2). … Read more…

Vistit to the IGBMC and Dynacure in Strassbourg

On March 24, 2016, members of  ZNM – Zusammen Stark e. V. and The Myotubular Trust met at IGBMC in Strasbourg to visit the laboratory of Jocelyn Laporte, where Myotubular Trust have been funding projects for a number of years. We had a tour of the IGBMC lab with Jocelyn Laporte, Belinda Cowling and Johann … Read more…